OrthoPediatrics

OrthoPediatrics Corp. is an orthopedic company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. It offers products relating to trauma and deformity, scoliosis, and sports medicine and other procedures. The company was founded by Erin Springer Yount and Nick A. Deeter in August 2006 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OrthoPediatrics achieves record revenue growth and eyes international expansion

OrthoPediatrics delivered strong financial performance in 2022, achieving profitability and record revenue growth despite challenges. With a focus on new product launches, international expansion, and surgeon training, the company is well-positioned for continued growth and profitability.

OrthoPediatrics reports robust Q1 earnings, eyes international growth opportunities

OrthoPediatrics had a strong Q1 2023, with increased revenue guidance for the full year. The company remains cautiously optimistic due to staffing dynamics. Focus on new product development, acquisitions, and addressing digital needs of children's hospitals highlight growth strategies.

OrthoPediatrics achieves record Q2 performance amidst growth challenges

OrthoPediatrics delivered strong Q2 results with record child assistance and revenue growth, driven by trauma, deformity, and international segments.
While facing challenges like atypical growth patterns and delays in product launches, the company is well-positioned to capitalize on opportunities in enabling technologies and international expansion.
The focus on long-term growth drivers and strategic acquisitions underscores OrthoPediatrics' commitment to sustainable growth and innovation in pediatric orthopedics.
Overall, OrthoPediatrics' performance highlights operational efficiency, market demand, and a clear path for future growth and expansion.

OrthoPediatrics achieves record revenue in Q3 2023, eyes continued growth

OrthoPediatrics reported strong financial performance in Q3 2023, with record revenue and EBITDA, positioning the company for future growth. Despite challenges in certain segments, opportunities in new product launches, international expansion, and surgeon training initiatives offer avenues for continued success. The company's positive outlook and robust pipeline indicate a promising trajectory for OrthoPediatrics.

OrthoPediatrics achieves record revenue and EBITDA, eyes international expansion

OrthoPediatrics delivered strong financial performance in 2023, setting revenue and EBITDA records. The company's strategic focus on sustainable growth, profitability, and diversification positions it well for future success.

OrthoPediatrics reports robust Q1 growth, raises full-year revenue guidance

OrthoPediatrics demonstrated strong performance in Q1 2024 with significant growth in patients helped, revenue, and key business segments. While facing challenges such as an EBITDA loss and increased expenses, the company's focus on growth, new product launches, and financial targets positions it well for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OrthoPediatrics Corp. (NASDAQ:KIDS ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Trip Taylor - Gilmartin Group David Bailey - President & Chief Executive Officer Fred Hite - Chief Financial Officer & Chief Operating Officer Conference Call Participants Matt O'Brien - Piper Sandler Joseph Conway - Needham & Company Operator Good morning and welcome to OrthoPediatrics Corporation's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

OrthoPediatrics Corp. (KIDS) Q3 2024 Earnings Call Transcript

The headline numbers for OrthoPediatrics (KIDS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, OrthoPediatrics (KIDS) Q3 Earnings: A Look at Key Metrics

OrthoPediatrics (KIDS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.13 per share a year ago.

OrthoPediatrics (KIDS) Reports Q3 Loss, Tops Revenue Estimates

WARSAW, Ind., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2024.

OrthoPediatrics Corp. Reports Third Quarter 2024 Financial Results and Increases Full Year 2024 Revenue Guidance

WARSAW, Ind., Oct. 23, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2024 financial results on Wednesday, November 6, 2024, after the market closes. OrthoPediatrics will host a conference call on Thursday, November 7, 2024, at 8:00 a.m. ET to discuss the results.

OrthoPediatrics Corp. to Report Third Quarter 2024 Financial Results on November 7, 2024

OrthoPediatrics (KIDS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes OrthoPediatrics (KIDS) a New Strong Buy Stock

OrthoPediatrics (KIDS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -15.65% in 4 Weeks, Here's Why You Should You Buy the Dip in OrthoPediatrics (KIDS)

OrthoPediatrics (KIDS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Bears are Losing Control Over OrthoPediatrics (KIDS), Here's Why It's a 'Buy' Now

The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in OrthoPediatrics (KIDS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does OrthoPediatrics (KIDS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect?

OrthoPediatrics recently launched its Enabling Technologies division, set to generate sustainable revenue growth and gain access to new markets and specialties beyond orthopedics.

KIDS Stock Gains From Its New Enabling Technologies Division Launch

Additional details to be discussed during the Company's Investor Day today, September 12, 2024 Additional details to be discussed during the Company's Investor Day today, September 12, 2024

OrthoPediatrics Corp. Announces Launch of Enabling Technologies Division

The consensus price target hints at a 31.2% upside potential for OrthoPediatrics (KIDS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 31.2% Upside in OrthoPediatrics (KIDS): Here's What You Should Know

WARSAW, Ind., Aug. 20, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced plans to host an investor day at 10:30am E.T. on September 12, 2024, in New York, New York. Management's presentation will provide updates on the Company's Specialty Bracing business strategy, product pipeline, and financial outlook and feature a KOL surgeon panel.

OrthoPediatrics Corp. to Host Investor Day on September 12, 2024

OrthoPediatrics Corp. (NASDAQ:KIDS ) Q2 2024 Earnings Conference Call August 6, 2024 8:00 AM ET Company Participants Trip Taylor - Gilmartin Group David Bailey - President & Chief Executive Officer Fred Hite - Chief Financial Officer & Chief Operating Officer Conference Call Participants Rick Wise - Stifel Ryan Zimmerman - BTIG Matthew O'Brien - Piper Sandler Mike Matson - Needham Dave Turkaly - Citizens JMP Ravi Misra - Truist Operator Good morning, and thank you for standing-by. Welcome to the Second Quarter 2024 OrthoPediatrics Earnings Conference Call.

OrthoPediatrics Corp. (KIDS) Q2 2024 Earnings Call Transcript

Although the revenue and EPS for OrthoPediatrics (KIDS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

OrthoPediatrics (KIDS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

OrthoPediatrics (KIDS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.19 per share a year ago.

OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates

WARSAW, Ind., Aug. 05, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the second quarter ended June 30, 2024.

OrthoPediatrics Corp. Reports Second Quarter 2024 Financial Results and Reaffirms Full Year 2024 Revenue Guidance

Term Loan and Private Placement of Convertible Notes Will Provide Up To $100 Million of Capital Term Loan and Private Placement of Convertible Notes Will Provide Up To $100 Million of Capital

OrthoPediatrics Corp. Announces Private Financing

WARSAW, Ind., July 22, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its second quarter 2024 financial results on Monday, August 5, 2024, after the market closes. OrthoPediatrics will host a conference call on Tuesday, August 6, 2024, at 8:00 a.m. ET to discuss the results.

OrthoPediatrics Corp. to Report Second Quarter 2024 Financial Results on August 6, 2024

OrthoPediatrics (KIDS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

OrthoPediatrics (KIDS) Soars 7.5%: Is Further Upside Left in the Stock?

WARSAW, Ind., June 04, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer is scheduled to participate in a fireside chat at the Truist Securities MedTech Conference, being held in Boston, MA.

OrthoPediatrics Corp. to Participate in the Truist Securities MedTech Conference

WARSAW, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its continued support of the combined 2024 Pediatric Orthopaedic Society of North America (“POSNA”) and European Paediatric Orthopaedic Society (“EPOS”) annual meeting as an Emerald sponsor.

OrthoPediatrics Corp. Continued Leading Sponsorship at 2024 EPOSNA Annual Meeting

OrthoPediatrics Corp. (NASDAQ:KIDS ) Q1 2024 Earnings Conference Call May 7, 2024 8:00 AM ET Company Participants David Bailey - President, Chief Executive Officer Fred Hite - Chief Financial Officer, Chief Operating Officer Trip Taylor - Gilmartin Group Conference Call Participants Ryan Zimmerman - BTIG Matthew O'Brien - Piper Sandler Rick Wise - Stifel Mike Matson - Needham & Company Dave Turkaly - Citizens JMP Sam Brodovsky - Truist Securities Operator Good morning. Welcome to OrthoPediatrics Corporation's First Quarter 2024 Earnings Conference Call.

OrthoPediatrics Corp. (KIDS) Q1 2024 Earnings Call Transcript

While the top- and bottom-line numbers for OrthoPediatrics (KIDS) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

OrthoPediatrics (KIDS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

OrthoPediatrics (KIDS) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.29 per share a year ago.

News for OrthoPediatrics Stock (KIDS)